KR20240093576A - 신규 트리메타지딘 염 - Google Patents
신규 트리메타지딘 염 Download PDFInfo
- Publication number
- KR20240093576A KR20240093576A KR1020247015968A KR20247015968A KR20240093576A KR 20240093576 A KR20240093576 A KR 20240093576A KR 1020247015968 A KR1020247015968 A KR 1020247015968A KR 20247015968 A KR20247015968 A KR 20247015968A KR 20240093576 A KR20240093576 A KR 20240093576A
- Authority
- KR
- South Korea
- Prior art keywords
- trimetazidine
- acid
- ppm
- salt
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21306465.2 | 2021-10-20 | ||
| EP21306465 | 2021-10-20 | ||
| PCT/EP2022/079054 WO2023066971A1 (en) | 2021-10-20 | 2022-10-19 | Novel trimetazidine salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240093576A true KR20240093576A (ko) | 2024-06-24 |
Family
ID=78592764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247015968A Pending KR20240093576A (ko) | 2021-10-20 | 2022-10-19 | 신규 트리메타지딘 염 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20250250245A1 (enExample) |
| EP (1) | EP4419510B1 (enExample) |
| JP (1) | JP2024539090A (enExample) |
| KR (1) | KR20240093576A (enExample) |
| CN (1) | CN118076591A (enExample) |
| AR (1) | AR127403A1 (enExample) |
| AU (1) | AU2022369026A1 (enExample) |
| CR (1) | CR20240157A (enExample) |
| DK (1) | DK4419510T3 (enExample) |
| ES (1) | ES3057370T3 (enExample) |
| HR (1) | HRP20251413T1 (enExample) |
| IL (1) | IL311916A (enExample) |
| LT (1) | LT4419510T (enExample) |
| MA (1) | MA66951B1 (enExample) |
| MX (1) | MX2024004714A (enExample) |
| PL (1) | PL4419510T3 (enExample) |
| PT (1) | PT4419510T (enExample) |
| RS (1) | RS67449B1 (enExample) |
| SI (1) | SI4419510T1 (enExample) |
| WO (1) | WO2023066971A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025106477A1 (en) * | 2023-11-14 | 2025-05-22 | Samsara Therapeutics Inc. | Novel autophagy inducing compounds and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104138376A (zh) * | 2013-05-06 | 2014-11-12 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种提高缺氧耐受力的缓释剂 |
| FR3027803B1 (fr) | 2014-11-05 | 2018-02-09 | Les Laboratoires Servier | Composition pharmaceutique comprenant un betabloquant et un inhibiteur de l'enzyme de conversion |
| CN105287564A (zh) * | 2015-09-06 | 2016-02-03 | 余祖江 | 一种防治肝病的西药复合物及其用途 |
| CN110183398B (zh) | 2019-05-14 | 2021-06-29 | 中南民族大学 | 一种曲美他嗪草酸盐及其制备方法和应用 |
| CN110105307B (zh) | 2019-05-14 | 2021-06-01 | 中南民族大学 | 一种曲美他嗪草酸盐及其制备方法和应用 |
| CN110054599B (zh) * | 2019-05-14 | 2021-05-07 | 中南民族大学 | 一种曲美他嗪草酸盐及其制备方法和应用 |
| CN112043691A (zh) * | 2019-06-06 | 2020-12-08 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种药物组合物及其用途 |
-
2022
- 2022-10-19 RS RS20251183A patent/RS67449B1/sr unknown
- 2022-10-19 MX MX2024004714A patent/MX2024004714A/es unknown
- 2022-10-19 CR CR20240157A patent/CR20240157A/es unknown
- 2022-10-19 LT LTEPPCT/EP2022/079054T patent/LT4419510T/lt unknown
- 2022-10-19 US US18/702,363 patent/US20250250245A1/en active Pending
- 2022-10-19 AR ARP220102840A patent/AR127403A1/es unknown
- 2022-10-19 EP EP22808665.8A patent/EP4419510B1/en active Active
- 2022-10-19 IL IL311916A patent/IL311916A/en unknown
- 2022-10-19 PL PL22808665.8T patent/PL4419510T3/pl unknown
- 2022-10-19 AU AU2022369026A patent/AU2022369026A1/en active Pending
- 2022-10-19 ES ES22808665T patent/ES3057370T3/es active Active
- 2022-10-19 SI SI202230206T patent/SI4419510T1/sl unknown
- 2022-10-19 PT PT228086658T patent/PT4419510T/pt unknown
- 2022-10-19 DK DK22808665.8T patent/DK4419510T3/da active
- 2022-10-19 HR HRP20251413TT patent/HRP20251413T1/hr unknown
- 2022-10-19 WO PCT/EP2022/079054 patent/WO2023066971A1/en not_active Ceased
- 2022-10-19 MA MA66951A patent/MA66951B1/fr unknown
- 2022-10-19 JP JP2024523404A patent/JP2024539090A/ja active Pending
- 2022-10-19 CN CN202280068113.8A patent/CN118076591A/zh active Pending
- 2022-10-19 KR KR1020247015968A patent/KR20240093576A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL311916A (en) | 2024-06-01 |
| CR20240157A (es) | 2024-05-22 |
| EP4419510B1 (en) | 2025-10-08 |
| ES3057370T3 (en) | 2026-03-02 |
| WO2023066971A1 (en) | 2023-04-27 |
| JP2024539090A (ja) | 2024-10-28 |
| LT4419510T (lt) | 2025-12-29 |
| CN118076591A (zh) | 2024-05-24 |
| CA3234743A1 (en) | 2023-04-27 |
| US20250250245A1 (en) | 2025-08-07 |
| RS67449B1 (sr) | 2025-12-31 |
| AR127403A1 (es) | 2024-01-17 |
| EP4419510A1 (en) | 2024-08-28 |
| HRP20251413T1 (hr) | 2025-12-19 |
| MA66951B1 (fr) | 2025-12-31 |
| AU2022369026A1 (en) | 2024-05-02 |
| PT4419510T (pt) | 2026-01-02 |
| SI4419510T1 (sl) | 2026-01-30 |
| MX2024004714A (es) | 2024-05-10 |
| DK4419510T3 (da) | 2025-11-17 |
| PL4419510T3 (pl) | 2026-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021201339B2 (en) | Fenfluramine compositions and methods of preparing the same | |
| KR20200074942A (ko) | 리보시클립 염 및 이의 고상 형태 | |
| CN115968370A (zh) | Iap拮抗剂化合物和中间体及其合成方法 | |
| US20250250245A1 (en) | Trimetazidine salts | |
| CA3234743C (en) | Novel trimetazidine salts | |
| KR100830002B1 (ko) | 시부트라민의 무기산염 | |
| CA3108007C (en) | Highly stable crystalline eltrombopag monoethanolamine salt form d1 | |
| KR101319516B1 (ko) | 퓨린 유도체 | |
| EA048901B1 (ru) | Новые соли триметазидина | |
| HK40115749A (en) | Novel trimetazidine salts | |
| HK40115749B (en) | Novel trimetazidine salts | |
| KR20260070540A (ko) | 환원형 β-니코틴아미드 모노뉴클레오티드 칼슘염의 다형체 및 이의 제조 방법과 용도 | |
| KR20250169304A (ko) | 신규 트리메타지딘 고체 상 | |
| HK40108623A (en) | Novel trimetazidine salts | |
| HK40130959A (en) | Novel trimetazidine solid phases | |
| KR20210073972A (ko) | (r)-2-((4-아미노페네틸)아미노)-1-페닐에탄올의 신규한 제조방법 | |
| US20240166654A1 (en) | Ruxolitinib crystal and pharmaceutical composition thereof | |
| KR20210058817A (ko) | 브로모도메인 억제제의 제조 방법 | |
| AU2024206378A1 (en) | Solid forms and methods of use | |
| CN113105504A (zh) | Remdesivir衍生物、其类似物及其制备方法与应用 | |
| WO2020086789A1 (en) | New crystalline polymorphs of rigosertib sodium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |